Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galvokimig - UCB Biopharma

Next Previous
Drug Profile

Galvokimig - UCB Biopharma

Alternative Names: Galvokimig-UCB Biopharma; UCB-9741

Latest Information Update: 23 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB Biopharma
  • Class Anti-inflammatories; Antibodies; Bispecific antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Atopic dermatitis

Most Recent Events

  • 18 Sep 2025 Efficacy and adverse event data from phase I/IIa trial in Atopic dermatitis released by UCB Biopharma
  • 18 Sep 2025 UCB Biopharma plans a phase IIb trial for Atopic dermatitis in 2025
  • 01 Jan 2025 UCB Biopharma completes a phase I trial in (indication) in Atopic dermatitis (In volunteers) in USA (SC) (NCT06315335)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top